Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial.

The HOPE-3 phase 3 randomized controlled trial evaluated deramiocel, a heart-derived cellular therapy, in patients with advanced Duchenne muscular dystrophy (DMD). Published in The Lancet, the double-blind, placebo-controlled study examined the cardiac and functional effects of this investigational treatment in a population with significant disease progression. The findings contribute to the evidence base for novel disease-modifying approaches in DMD, a condition that often involves physical therapy as part of multidisciplinary management.

Read full article at PubMed / Lancet ↗

About this summary. The text above is a short summary written for this site. The original article is hosted by PubMed / Lancet at the link above; this site does not reproduce the full article. Verify against the source before relying on specific details.